Philips has received clearance from the FDA for its artificial-intelligence-powered MRI platform geared toward head and neck cancers.

Though only about an inch in diameter, BioIntelliSense’s BioButton wearable device for remote monitoring boasts an impressive reach—and one that’s still growing, thanks to the company’s recent acquisition of additional patient-tracking software.

Oxford Nanopore Technologies is rolling out a new version of its high-throughput benchtop DNA sequencer with the goal of providing genetic data to a wide variety of researchers and scientific areas.

Scientists have discovered that nicotine accumulation in the intestines of tobacco smokers drives the progression of nonalcoholic steatohepatitis, or NASH—and that a nicotine-degrading gut bacterium could be useful in treating the disease.

Medtronic has secured a new approval from the FDA that expands the flexibility of its pacemaker hardware, allowing it to tap into the heart’s natural electrical signals.

Whisper it, but biotech SPACs appear to be back in fashion. The latest is cancer-focused Aum Biosciences, which is merging with blank check company Mountain Crest Acquisition to put its MNK and TRK inhibitors into phase 2 testing.

Ten months after revealing a phase 3 flop, Summit Therapeutics has shared data from an antibiotic trial and framed it as evidence of a potential need to change how anti-infectives are developed and assessed.

Gilead’s Kite Pharma has tied down a licensing deal for Refuge Biotechnologies’ gene expression platform in hopes of developing new blood cancer treatments and plans to take flight with a new generation of CAR-Ts.

A new artificial intelligence tool is aiming to improve the delivery of peripheral nerve block (PNB) injections, which may in many surgical cases be a superior option for local anesthesia or pain relief, but which aren’t always used since they require precise placement.

A series of studies in recent years have used objective data to back up decades’ worth of anecdotal evidence describing widespread racial biases in the delivery of healthcare. Patients, doctors and medtech developers are now keenly aware, for example, of the potential inaccuracies of pulse oximeters when used to measure blood oxygen levels through the skin of Black patients.